NCT03539536: Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 270 taking part
- Started
- 10 Oct 2018
- Primary completion
- Jul 2026
- Arms
- Telisotuzumab vedotin
- Results
- None posted
- 29 May 2018: Trial registered
- 10 Oct 2018: Trial started